Evidence map›Paper›PMID 41757032›Full record

ArticlebioRxiv : the preprint server for biology2026

Oral 4'fluorouridine provides postexposure protection against lethal Nipah virus infection.

Robert W Cross, Declan D Pigeaud, Victoriya Borisevich, Krystle N Agans, Mack B Harrison, Rachel O'Toole, Abhishek N Prasad, Thomas W Geisbert

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robert W CrossGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Declan D PigeaudGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Victoriya BorisevichGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Krystle N AgansGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Mack B HarrisonGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Rachel O'TooleGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Abhishek N PrasadGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
Thomas W GeisbertGalveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Thomas Gary Ksiazek · 2011 to 2026
$208.8M
NIAID NIH HHS UC7 AI094660
6 · The paper itself

Abstract

There are no approved medical countermeasures for combatting Nipah virus (NiV) which causes regular outbreaks in humans and animals in South and Southeast Asia with mortality rates in humans ranging from 40% to more than 90%. Recently, it was shown that 4'-fluorouridine (4'-FlU; EIDD-2749), an orally available ribonucleoside analog, protected guinea pigs and nonhuman primates from lethal challenge with Lassa virus and that 4'-FlU has

Identifiers

PMID41757032
PMCPMC12934678

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.